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DISCUSSION 
Professor Grayston: I am very sympathetic with Dr 
Harnmerschlag’s inability to support her isolation 
results with the patient developing antibody, since it 
suggests that the isolations are not associated with 
disease. However, it is only h m  her group that we have 
been hearing about C. pneumoniae isolations not being 
associated with antibody response. 
Our laboratory results from four studies of acute 
respiratory disease are shown in Table 1. The first two 
studies are fiom University of Washington students, one 
at an epidemic time and one at a more recent endemic 
time. In the Seattle HMO, Group Health, a large 
number of adults were studied from 1985 to 1987. 
Finally, there is the study of a Finnish rmlitary epidemic. 
We were able either to isolate or show PCR positivity 
in 60-70% of patients who were MIF positive in each 
of these studies. We found no patients who were MIF 
negative from whom there was an isolation- or a PCR- 
positive result. These results have been published in 
decal [1-4] and are the expected results with an in- 
fectious disease: namely, the development of measur- 
able antibody in association with infection. 
With a serologic test, particularly one similar to the 
MIF test, each laboratory should develop its own 
criteria for what is positive and what is negative, and 
not take somebody else’s criteria. There will be varia- 
tions among laboratories in titers obtained. 
It is important to realize that the MIF test is not a 
test that can be set up in any c h c a l  laboratory. It is a 
challenging test that requires experienced microscopic 
interpretation. It is not a test which Merent tech- 
nicians can be left on their own to run. It has to be very 
carefully supervised ifyou are going to get good results. 
It is incorrect to say that the MIF is not a specific test. 
AfZer all, we would not know that there were 18 
serovars of C. trachomatis if it were not for the MIF test. 
C. pneumoniae was discovered as a respiratory pathogen 
by the MIF test. It is true that some workers have 
reported non-specific results with the Chlamydia MIF 
test. It is important to take advantage of having several 
antigens under t h i s  same drop of serum to compare the 
type offluorescence reaction. One way I judge whether 
the test is being done properly is whether the 
laboratory can separate the C. trachomatis irnmunotypes. 
If you can separate them, you have no problem in 
separating different species. 
Dr Hammerschlag: We find this problem mostly in 
children. It has not really been our experience in adults. 
We find most adults do have antibody. The problem is 
with chromc infection. The group working at Johns 
Hopkins University have had some similar results to 
ours and so have other people who have looked at 
children. When I can demonstrate a four-fold rise I do 
believe it. Incidentally, if you are seeing somebody in 
your STD clinic for Chlamydia mfection, how do we 
make the diagnosis? Since we need to treat these 
infections, the bottom line will be identification of the 
organism. 
Question: Did you find Chlamydia pneumoniae- 
positive cultures in healthy adults? 
Dt Hammerschlag: We have looked at asymptomatic 
adults and we have a background rate of about 2%. Ths 
is similar to what has been reported from Sweden. We 
also looked at children. We found about 5%. I am not 
surprised. 11: is possible that these individuals may have 
had an acute infection in the past and they remain 
positive after resolution because treatment can fail. The 
point is in distinguishmg infection from disease. When 
we look at symptomatic infections, isolation rates are 
Table 1 Chlamydia pneumoniae diagnostic test results for four studies of acute respiratory 
disease (AFW). 
No. ARD MIF MIF positive, MIF negative, 
patients serology isolation or isolation or 
studied positive PCR positive PCR positive 
University of Washington 
students - epidemic [I] 54 12 9 0 
students - endemic [2] 105 5 3 0 
adults [3] 743 21 15 0 
University of Washington 
Group Health Seattle 
Military epidemic Kajanni, 
Finland [4] 67 37 23 0 
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close to 20% in some populations, such as chlldren with 
pneumonia, children with asthma, adults with bron- 
chtis, adults with pneumonia, chddren and adults with 
cystic fibrosis undergoing acute exacerbation, and 
chlldren with sickle cell disease and acute chest 
syndrome. As with other Chlamydia infections, in the 
appropriate host there probably is a background rate 
of subclinical mfection. 
Question: Do you have the same results with culture 
and PCR in adults who have no symptoms? 
Professor Saikku: In Scandinavian countries it is 
quite ddlicult to isolate C. pneumoniae. We have tested 
bronchal lavages from patients, and isolation of C. 
pneumoniae is very rare. Only in chronic bronchitis has 
PCR been positive in about 50% of the patients. Dr 
Persson in Malmo got his first isolate after testing 600 
specimens. Professor Mar& in Uppsala commented to 
me: ‘What is wrong with C. pneumoniae; we have 
antibodies but we are not able to isolate the agent?’ 
Professor Grayston: I have been asked at this meeting 
a couple of times about the ease of isolation of C. 
pneumoniae. Any laboratory that is having trouble 
isolating the organism should not feel badly, because 
that is the usual experience. As Professor Saikku has 
reported h m  Scandinavia, many US laboratories with 
extensive experience of isolating C. trachomatis have had 
great Miculty in isolating C. pneumoniae. When Dr 
Hammerschlag reports isolation rates of 20% &om 
various diseases and 5% from asymptomatic children, 
these results are unique and have not been confirmed. 
In regard to the question of asymptomatic carriage 
of C. pneumoniae, I would agree with Dr Hammer- 
schlag’s results that there may be up to 1% of persons 
h m  whom you can isolate the organism who may well 
be carriers. Perhaps they are convalescent carriers. 
Perhaps they are longer-term carriers. We have made 
two isolates &om asymptomatic persons. They both 
were contacts of infected persons. One had antibody 
and one did not. Since 6-9% of children 5 to 14 years 
of age show C. pneumoniae antibody conversion yearly, 
and many are asymptomatic, it should be possible 
occasionally to isolate the organism, but I believe it is 
uncommon. Actually, I think Dr Hammerschlag had 
only three or four that looked like carriers; is that true? 
Dr Hammerschlag: We had two individuals as part 
of a study of 104, so that was about 2%. It is hard to 
get asymptomatic children. We also looked for controls 
in a coronary artery disease study that we were doing. 
We had one out of about 20. We also had a laboratory 
accident where we managed to destroy a c e n t r ~ g e  and 
aerosolize a flask of C. pneumoniae. The two people in 
the laboratory both got infected. 
Professor Grayston: Maybe they are the ones who 
are giving it to other people. 
Dr Hammerschlag: That is the only laboratory- 
acquired infection that we are familiar with. In our 
laboratory everybody who comes in is cultured before 
they s t a r t  working with us, as well as getting baseline 
antibody levels. 
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